HOME >> BIOLOGY >> NEWS
Hemocellular Therapeutics establishes licensing agreement with UNC, ECU

CHAPEL HILL -- Hemocellular Therapeutics, expected to produce the first platelet-based therapeutic available to doctors for the immediate treatment of active bleeding, has established an exclusive licensing agreement with the University of North Carolina at Chapel Hill and East Carolina University, company officials recently announced.

The agreement recognizes key technology developed by researchers at the two universities as central to the N.C. company's planned creation of lyophilized, or "freeze-dried," human platelets the component of blood primarily responsible for initiation of coagulation. As a part of the exclusive license agreement, both universities received equity in Hemocellular and will share in royalties on the eventual sale of products.

Hemocellular's freeze-dried platelets are the result of a decade of research supported by initial federal research funding of $10 million.

The company's scientific founders, Dr. Arthur P. Bode of ECU and Dr. Thomas H. Fischer of UNC, have led the research efforts. Bode, who received his doctorate in experimental pathology from UNC, has served as ECU's scientific director of clinical coagulation programs for 15 years.

Fischer is scientific director of UNC's Francis Owen Research Laboratory, where researchers discovered the molecular cell membrane cross-linking technology crucial to Hemocellular's product development, said Richard A. Basile, chief executive officer of the company, and the initial extensive series of trials have taken place at that lab.

"The Francis Owen lab has a worldwide reputation in the field of coagulation therapeutics. We are extremely fortunate to have researchers affiliated with this lab informing our efforts to bring this technology to health-care settings as rapidly and responsibly as possible," he said.

Basile added that the licensing agreement is key in advancing platelet development to the next stage: human clinical trials. No other func
'"/>

Contact: Deb Saine
919-962-8415
University of North Carolina at Chapel Hill
15-May-2003


Page: 1 2 3

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
4. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
5. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
6. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
7. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
8. Immerge BioTherapeutics announces identification of PERV receptor
9. Acorda Therapeutics acquires CeNeS neuregulin products
10. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
11. Genome Therapeutics, University of Southampton and Schering-Plough identify novel asthma gene

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: